Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK40118 in EGFR+ Advanced NSCLC
NCT06050980Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK40118 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 52 months, Dose-Limiting Toxicities at 52 months and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
HSK40118
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06050980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050980.